NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.95% | -3.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.49% | -2.65% | |||
| Operating Income | -15.49% | 2.65% | |||
| Income Before Tax | -23.68% | 5.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.68% | 5.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.68% | 5.66% | |||
| EBIT | -15.49% | 2.65% | |||
| EBITDA | -16.18% | 3.06% | |||
| EPS Basic | -10.15% | 8.37% | |||
| Normalized Basic EPS | -10.57% | 8.89% | |||
| EPS Diluted | -10.15% | 8.37% | |||
| Normalized Diluted EPS | -10.57% | 8.89% | |||
| Average Basic Shares Outstanding | 11.89% | 3.32% | |||
| Average Diluted Shares Outstanding | 11.89% | 3.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||